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Abstract
Background: Excessive maternal pre-pregnancy and gestational weight gain are related to pregnancy- and birth
outcomes. The interpregnancy time window offers a unique opportunity to intervene in order to acquire a healthy
lifestyle before the start of a new pregnancy.
Methods: INTER-ACT is an e-health driven multicentre randomised controlled intervention trial targeting women at high
risk of pregnancy- and birth related complications. Eligible women are recruited for the study at day 2 or 3 postpartum.
At week 6 postpartum, participants are randomised into the intervention or control arm of the study. The intervention
focuses on weight, diet, physical activity and mental well-being, and comprises face-to-face coaching, in which
behavioural change techniques are central, and use of a mobile application, which is Bluetooth-connected to a weighing
scale and activity tracker. The intervention is rolled out postpartum (4 coaching sessions between week 6 and month 6)
and in a new pregnancy (3 coaching sessions, one in each trimester of pregnancy); the mobile app is used throughout
the two intervention phases. Data collection includes data from the medical record of the participants (pregnancy
outcomes and medical history), anthropometric data (height, weight, waist- and hip circumferences, skinfold thickness
and body composition by bio-electrical impedance analysis), data from the mobile app (physical activity and weight;
intervention group only) and questionnaires (socio-demographics, breastfeeding, food intake, physical activity, lifestyle,
psychosocial factors and process evaluation). Medical record data are collected at inclusion and at delivery of the
subsequent pregnancy. All other data are collected at week 6 and month 6 postpartum and every subsequent 6 months
until a new pregnancy, and in every trimester in the new pregnancy. Primary outcome is the composite endpoint score
of pregnancy-induced hypertension, gestational diabetes mellitus, caesarean section, and large-for-gestational-age infant
in the subsequent pregnancy.
Discussion: INTER-ACT is a unique randomised controlled lifestyle intervention trial in its implementation between
pregnancies and during the subsequent pregnancy, with an e-health driven approach.
Trial registration: ClinicalTrials.gov Identifier: NCT02989142. Registered August 2016.
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Background
Maternal pre-pregnancy weight is related to pregnancy-
and birth outcomes. An excessive weight before concep-
tion increases the risk for pregnancy- and birth related
complications such as gestational diabetes mellitus
(GDM), pregnancy-induced hypertension (PIH), caesar-
ean section (CS), or a large-for-gestational age (LGA) in-
fant [1–4]. Besides, excessive gestational weight gain
(EGWG), i.e. a gestational weight gain (GWG) higher
than the recommended GWG by the Institute Of Medi-
cine (IOM) [5], is also associated with these perinatal
complications [6–8]. Both the pre-pregnancy BMI and
gestational weight gain (GWG) are thus considerable
risk factors of pregnancy and birth complications. Be-
tween 2009 and 2014, the Flanders Study centre Peri-
natal Epidemiology (SPE) collected data of almost
400.000 singleton pregnancies in Flanders, Belgium, on
the combined association of GWG and pre-pregnancy
BMI with the prevalence of the composite outcome of
pregnancy and birth complications (i.e. at least one of
four perinatal outcomes PIH, GDM, CS and/or LGA in-
fant). The prevalence of the composite perinatal out-
come was 26% in women with a normal BMI and an
adequate GWG; 34% in women with a normal BMI but
with an excessive GWG; and 66% in women with class
III obesity (BMI ≥ 40) and excessive GWG [SPE, 2016 in
progress]. A Norwegian study reported similar findings.
Haugen et al. [9] found that normal weight and over-
weight women with EGWG had an increased risk for
PIH, preeclampsia, CS, high birth weight (>4500 g) and
LGA infant. Moreover, women of all BMI classes and
with EGWG, except underweight women, had an in-
creased risk of more than 2 kg postpartum weight reten-
tion (PPWR) at 18 months postpartum [9]. Conversely, a
more recent study from Xiong et al. reported an in-
creased likelihood of CS in underweight or normal
weight women with EGWG compared to overweight or
obese women EGWG [10]. Thus, these results highlight
the importance of adequate GWG in all BMI groups.
Based on the guidelines of the Institute of Medicine
(IOM) [5], one in three women in Flanders, Belgium,
has excessive GWG: 25% in normal pre-pregnancy BMI,
58% in pre-pregnancy overweight, and 54% in pre-
pregnancy obesity [11]. Half of the women with exces-
sive GWG do not return to their pre-pregnancy weight
after delivery, resulting in a doubled risk for pregnancy-
and birth related complications in the next pregnancy
[12]. Retention of the excessive weight gained during
pregnancy (i.e. PPWR) can result in obesity and an
increased risk of chronic disease in later life [13–17].
Additionally, maternal obesity negatively affects the
health of the offspring in childhood and in adulthood, by
increasing the risk of obesity and the related risks of
non-communicable diseases. Maternal obesity might
therefore result in a vicious circle of obesity throughout
generations [4, 18, 19].
Several lifestyle interventions have been implemented
during pregnancy in an attempt to reduce GWG and
prevent pregnancy- and birth related complications. Al-
though these interventions showed moderate beneficial
effects on GWG, they had no significant impact on preg-
nancy- and birth related complications [20], potentially
due to the limited time window [21, 22]. Therefore, the
international community of health experts has called for
strategies that already intervene in the pre-conception
period in order to timely acquire a healthy lifestyle and
weight loss [1]. However, such strategies are still scarce
[20], possibly due to unpredictability of becoming preg-
nant and not being linked to the health care system pre-
conceptionally [23]. The few existing studies, though,
show promising results in intervening during the pre-
conception period [24–27]. An opportunity to overcome
the barrier of reaching women in their preconception
period, is to commence interventions already in the
postpartum period and continuing until the next preg-
nancy. Such interpregnancy interventions could poten-
tially be a unique strategy to acquire a healthy lifestyle
before a subsequent pregnancy starts.
Effective lifestyle interventions for weight management
among postpartum women are usually based on a com-
bination of diet and physical activity [28–30]. Ideally, such
lifestyle interventions go beyond education or advice alone
and integrate behavioural change techniques such as goal
setting, self-monitoring and feedback [25, 31]. Mobile
applications are excellent tools to incorporate such behav-
ioural change techniques for intervention efforts promot-
ing a healthy lifestyle [32] that have been found effective
in health behaviour change and weight loss [33].
The interpregnAncy Coaching for a healthy fuTure
(INTER-ACT) intervention is an e-health driven and
face-to-face combined coaching program that is imple-
mented between two pregnancies and during the subse-
quent pregnancy of women with an excessive GWG in
the previous pregnancy. The main aim of this study is to
assess the effectiveness of the INTER-ACT intervention
on the composite outcomes score (GDM, PIH, CS,
LGA) in the next pregnancy. This will be evaluated
through a randomised controlled trial with an interven-
tion- and control arm.
Methods
Study setting
INTER-ACT is a multi-centre randomised controlled
trial in which six hospitals from three provinces
(Leuven, Antwerp and Limburg) in the Flanders region of
Belgium are involved: University Hospital Leuven,
University Hospital Antwerp, GasthuisZusters Hospitals
Antwerp, St-Franciscus Hospital in Heusden-Zolder, Jessa
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Hospital in Hasselt, and Hospital Oost-Limburg in Genk.
These university, regional, or peripheral hospitals deliver
each year between 900 and 2600 new-borns. Recruitment
of participants takes place in these hospitals. Baseline
measurements, the intervention, and follow-up measure-
ments take place in the hospitals, private clinics, ‘Kind &
Gezin’ (Child & Family) organisations, or at home, de-
pending on the preference of the participant.
Recruitment and eligibility criteria
Study midwives from the participating hospitals are re-
sponsible for the recruitment of participants at day 2 or
3 postpartum. To optimise recruitment, flyers and post-
ers are placed in the waiting rooms of the participating
hospitals in order to inform potential participants.
Inclusion criteria for participation in the study are the
following: women aged ≥18 years; excessive gestational
weight gain (above the IOM recommendations [5]) in the
previous pregnancy; wish for a next pregnancy not ex-
cluded; proficiency of Dutch language; being able to use a
smartphone. Exclusion criteria for participation are the
following: unable or unwilling to give informed consent;
no access to internet; requirement for complex medical
diets; history of- or planned bariatric surgery; chronic dis-
orders (e.g. diabetes mellitus type 1 or 2, thyroid disease,
renal disease); significant psychiatric disorder; previous
stillbirth. Women with twin pregnancies in either the
pregnancy preceding the intervention or the subsequent
pregnancy are excluded from the study. Participants can
not follow other lifestyle interventions during their partici-
pation in the INTER-ACT study.
Randomisation
After inclusion at day 2 or 3 postpartum, an electronic data
capture system (CASTOR) will randomise participants in
the intervention or control group. Randomisation is re-
vealed at week 6 postpartum. Due to the nature of the
intervention (i.e. coaching sessions and use of mobile app,
weighing scale and activity tracker), no blinding is involved
in this study.
Intervention
The intervention consists of two intervention phases. The
first intervention phase starts at 6 weeks postpartum and
lasts until 6 months postpartum. The second intervention
phase starts before the 15th week of the next pregnancy
and lasts until the 35th week of the pregnancy. A devi-
ation of 2 weeks before or after the planned time point
is allowed. Both intervention phases comprise face-to-
face coaching and use of a mobile application. Between
the two intervention phases, participants in the inter-
vention group receive motivational reminders by e-mail
every 3 months.
Face-to-face coaching
During both intervention periods, women receive face-to-
face coaching sessions: four during the interpregnancy
period and three during the next pregnancy (Fig. 1). Coa-
ches trained in motivational interviewing and behavioural
change techniques conduct the coaching sessions. During
the coaching sessions, the participant is sensitised about
the benefits of a healthy lifestyle and the adoption of a
healthy lifestyle is stimulated. SMART (Specific, Measur-
able, Achievable, Relevant and Time specific) goal setting,
action planning and reinforcement support the adoption
of a healthy lifestyle. Besides, potential barriers to achiev-
ing goals or a healthy lifestyle are identified as well as
individually tailored solutions to overcome these barriers.
The data from the mobile app, i.e. the evolution of body
weight, physical activity and mental well-being, support
these coaching sessions.
Mobile application
The mobile app runs throughout the intervention pe-
riods and consists of four domains: nutrition, physical
activity, weight, and mental wellbeing. In the nutrition
domain, the participant sets nutrition goals based on the
Belgian ‘active food triangle’ [34]. If applicable, the nutri-
tion goals are adapted for lactating or pregnant women.
On a daily basis, the participant can indicate whether or
not she achieved her nutrition goal. In the physical activity
domain, the participant sets a goal regarding the number
of steps she wants to achieve every day. A Bluetooth-
connected activity and sleep tracker (Withings GO™) reg-
isters the participant’s activity and sleep, and allows the
app to assess whether the physical activity goal is reached.
Weight is recorded by a Bluetooth-connected weighing
scale (Body Cardio Withings™). In the mental wellbeing
domain, the participant can indicate her mood by choos-
ing one out of five emoticons that express different mood
states. Besides, the participant can indicate her stress level
on a stress meter in the shape of a thermometer. Custom
made tips are sent to support the participant in achieving
her nutrition and physical activity goals. Additionally,
based on the participant’s progress and mood state, the
app sends positive coaching messages in order to further
motivate the participant. The app development and pilot
study of the app including results from evaluation ques-
tionnaires will be described in a subsequent paper.
Ensuring adherence
Adherence to the intervention is enhanced in several
ways. Firstly, the coaching sessions coincide with the
postnatal follow-up visit and government vaccine
scheme (in the interpregnancy phase) and routine ultra-
sound scans during the 1st, 2nd and 3rd trimester of preg-
nancy (in the new pregnancy phase) in order to reduce
barriers to attend the sessions. Secondly, the participants
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can choose the study location of their preference: at the
hospital, private clinic, ‘Child & Family’ organisation, or at
the home of the participant. Thirdly, between the two inter-
vention phases, adherence to physical activity and healthy
nutrition behaviour are stimulated by sending 3-monthly
motivational coaching messages to the participant.
Participant timeline
Women are recruited at day 2 or 3 postpartum. Coaching
sessions take place at week 6, week 8, week 12 and month
6 postpartum. Subsequently, coaching sessions take place
before week 15, week 20 and week 35 in the next preg-
nancy. The mobile app is used from week 6 to month 6
postpartum and in the next pregnancy (Fig. 1).
Outcomes
In this RCT, we aim to evaluate a composite outcome as
primary outcome, of which at least one of the following
outcomes occurs in the subsequent pregnancy:
 Pregnancy-induced hypertension (PIH): new-onset
elevations of blood pressure (systolic blood pressure >
140 mmHg and diastolic blood pressure >90 mmHg)
after 20 weeks of gestation without significant
proteinuria [35].
 Gestational diabetes mellitus (GDM): is defined as
any degree of glucose intolerance with onset or first
recognition during pregnancy [36]. GDM is
diagnosed at 24–28 weeks of gestation with the two
Fig. 1 Study design of the INTER-ACT randomised controlled trial
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steps screening strategy which consists of a 50 g
glucose challenge test (GCT) and a 2-h 75 g oral
glucose tolerance test (OGTT). GDM is diagnosed
upon an abnormal GCT (≥ 140 mg/dl) followed by
an abnormal OGTT (≥ 153 mg/dl) based on the
VDV-VVOG-Domus Medica consensus 2012 and
IADPSG criteria [37].
 Caesarean section (CS): surgical procedure in which
a foetus is delivered through an incision in the
mother’s abdomen and uterus.
 Large-for-gestational-age baby (LGA): birth weight
>90th percentile on Flemish sex- and parity-adjusted
growth charts [38].








 Quality of life
 Mental wellbeing
Sample size
The primary endpoint is the composite endpoint of selected
pregnancy- and birth-related complications: PIH, GDM, CS
and LGA. PIH and GDM are assessed during pregnancy;
CS and LGA are determined at time of delivery (Fig. 1). In
order to find a significant difference between the interven-
tion and control arm in the rate of the selected pregnancy-
and birth-related complications (composite endpoint), as-
suming a 42% complication rate in the intervention arm
and 30% in the control arm (1/4 relative reduction), with a
statistical power of 80% and significance level of 0.05, we
need 500 women with a next (second) delivery: 250 women
in the intervention arm and 250 women in the control arm.
The figures for mean duration between birth and start
of a new pregnancy vary around 18 to 24 months. We
assume that 2/3 of the included women have a next de-
livery within 3 years since inclusion in the trial. We also
take into account a 30% drop-out rate during follow-up
till end of the next pregnancy. In order to obtain 500
women with a next delivery, taking into account a 30%
drop-out and only 65% having a next pregnancy within
3 years, we need to include 500x(1/0.65)x(1/0.7) = 1100
women: 550 women per arm.
Data collection
Time of data collection
Clinical data (i.e. medical record data and anthropomet-
ric data) and non-clinical data (i.e. data from the mobile
app and self-administered questionnaires) are collected
at day 2–3, week 6, and month 6 postpartum, every sub-
sequent 6 months until the next pregnancy, and at week
<15, 20, and 35 during the next pregnancy (Fig. 1). Devi-
ation of 2 weeks before or after the planned time point
is allowed.
At inclusion (day 2 or 3 postpartum) and at the end of
the subsequent pregnancy, data will be collected from the
medical record. During each coaching session, data from
the mobile app will be collected (intervention group only).
During all measurement moments (except day 2/3 and de-
livery of the next pregnancy) anthropometric data and
self-administered questionnaires are collected (Fig. 1).
Medical record data
Data from the medical record comprise pre-pregnancy
weight, pregnancy weight gain, pregnancy- and birth
outcomes, data of the new-born such as birthweight and
LGA, familial medical history (familial type 2 diabetes
mellitus, familial hypertension), chronic disease, psycho-
logical history; comorbidity; use of medication; medical
history of (previous) pregnancy (GCT, OGTT, GDM,
PIH, CS, proteinuria (>300 mg/24 h), preeclampsia, pre-
term delivery (<37 weeks of gestation) and miscarriage).
Anthropometric data
The anthropometric data consist of maternal weight,
height, skinfold thickness, waist and hip circumference,
body composition, and blood pressure. Maternal height
will be measured by a Seca-213 Leicester stadiometer.
Maternal weight and body composition (fat mass, fat free
mass, muscle mass, extra-cellular water, intra-cellular
water, organ fat and phase angle) will be measured with
the Tanita MC 780 SMA bio-electric impedance analysis
device. Skinfold thickness of the subscapular, suprailiac,
biceps, and triceps will be measured with the Harpenden
skinfold calliper and evaluated with the Harpenden
skinfold calliper software program. Waist and hip circum-
ferences are measured with a Seca 201 measuring tape in
order to estimate abdominal body fat. Blood pressure is
measured using the Microlife BP A150 AFIB device. All
measurements will be performed according to the stand-
ard operating procedures to ensure data quality.
Mobile app data
Data from the mobile app, i.e. self-monitored weight,
physical activity, emotional status, and stress level will be
transferred to the secured INTER-ACT website where
coaches can retrieve relevant data such as the self-
monitored weight and the amount of physical activity.
Questionnaires data
A link to the self-administered questionnaires will be sent
by e-mail or text message a few days before the study visit
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so that the participant can complete the questionnaires
online before the study visit. Uncompleted questionnaires
can be (further) completed during the study visit.
Socio-demographics questionnaire: assesses ethni-
city, marital status, level of education and employment
status.
Breastfeeding questionnaire: is based on existing
questionnaires by Guelinckx et al. [39] and Bogaerts et
al. (unpublished) and assesses type of infant feeding (i.e.
breastfeeding, bottle-feeding or a combination), number
of feedings per day, duration of having given/giving
breastfeeding in weeks, and motives for cessation of
breastfeeding.
Food Frequency Questionnaire: is developed and vali-
dated by Matthys et al. [40] and evaluates on the basis of
25 food items frequency of food intake (per day, per week
or per month) and portion size (in gram or millilitre).
Kaiser Physical Activity Survey (KPAS): is validated
for both pregnant and non-pregnant populations [41,
42] and assesses multiple domains of physical activity
(household/caregiving, occupational, active living and
sports/exercise).
Lifestyle behaviour questionnaire: is based on the
questionnaires of the DALI study [43] and evaluates
smoking behaviour, alcohol use, sleep duration and qual-
ity of sleep, and following a specific diet.
Short form State Trait Anxiety Inventory six item
(sSTAI-6): measures anxiety symptoms, is validated to
the original State Trait Anxiety Inventory (STAI) ques-
tionnaire [44] and is reliable and valid for use in the
perinatal period [45].
Edinburgh Postnatal Depression Scale (EPDS): is a
reliable and valid 10-item questionnaire that screens
women for symptoms of emotional distress during preg-
nancy and the postnatal period [46–48].
Sense of Coherence (SOC): is measured with the 13-
item SOC questionnaire. The SOC-13 assesses compre-
hensibility, manageability, and meaningfulness of one’s
life [49, 50]. It is a valid instrument used for non-
pregnant and pregnant populations [51].
Linear Analog Scale (LAS): assesses quality of life by
a vertically oriented scale with the lowest score 0, repre-
senting a poor quality of life, and the highest score 100
which represent a good quality of life [52].
Process evaluation questionnaire: is administered at
the end of both intervention periods and evaluates the
usability of the mobile app by the System Usability Scale
[53], the participants’ experience with the app (i.e. the
content of the app) and the face-to-face coaching.
Safety parameters
Possible adverse events associated with the intervention
can be exercise-related adverse events or adverse events
related to a rapid weight loss over a short period of time.
Moreover, although the EPDS questionnaire is a screen-
ing tool and not a diagnostic tool for depression, a posi-
tive response on question 10 of the EPDS questionnaire,
i.e. having suicidal thoughts, is considered alarming and
will be reported to the principal investigator (PI). Based
on the result and clinical judgment by the PI, women
will be referred to a specialised health practitioner.
Data management
The data from the questionnaires, the anthropometric
data and medical record will be entered and stored in a
full Good Clinical Practice (GCP) compliant Electronic
Data Capture system, i.e. the CASTOR electronic case
report form (eCRF). The data of the mobile application
(i.e. physical activity from the activity tracker, weight
evolution and mood status) of the participants can be re-
trieved from the secured website of INTER-ACT, of
which only the research team and the participant can
have access. Length and weight after delivery will be
transferred from the eCRF to the mobile application in
order to be able to calculate BMI and show weight
curves. In case of no database access, data will be en-
tered on paper CRF and subsequently entered into the
data system when access is possible.
Statistics
All analyses will be carried out using the intention-to-
treat principle with data from all participants enrolled in
the study. The statistical software SAS version 9.4 will
be used. Descriptive statistics for baseline values in the
two arms will be presented. There will be no tests of
statistical significance or confidence intervals for differ-
ences between the two arms, as these are randomised
groups. The drop-out rate will be assessed and com-
pared between the two arms. The composite endpoint
consists of occurrence of at least one of the following
four major pregnancy and birth related complications, at
time of next pregnancy: PIH, GDM, CS, and LGA. The
rate of the composite endpoint will be calculated and
95% confidence intervals provided in intervention and
control arm: 1) in all included patients (intent-to-treat),
2) in all patients completed a next pregnancy. If drop-
out rates, reason for drop-out, next pregnancy rates dif-
fer between the intervention arm and control arm, the
rate of the composite endpoint in patients with a next
pregnancy has to be interpreted carefully.
A full statistical analysis plan will be written by the
trial statistician prior to any analysis being undertaken.
We will report data in line with the Consolidated Stan-
dards of Reporting Trials (CONSORT) 2010 Statement
[54] and a P-values <0.05 will be considered statistically
significant.
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Discussion
Excessive weight before and during pregnancy is a public
health threat since it may lead to pregnancy- and birth re-
lated complications such as pregnancy-induced hyperten-
sion, gestational diabetes mellitus, caesarean section, and
large for gestational age infants in the short term and
weight-related chronic diseases in the long run. Moreover,
maternal obesity may lead to inter-generational cycles of
obesity through intra-uterine programming of the foetus.
Therefore it is essential to timely implement lifestyle inter-
ventions targeting high-risk groups.
INTER-ACT is a unique lifestyle intervention that fo-
cuses on weight, diet, physical activity and mental well-
being between pregnancies and during a subsequent
pregnancy with the aim to reduce pregnancy- and birth
related complications. The intervention especially fo-
cuses on those who are most at risk of these complica-
tions in a subsequent pregnancy: women with excessive
gestational weight gain during their previous pregnancy.
Strengths of this study can be found in 1) the design
of this e-health driven randomised controlled trial, 2)
the six participating study sites that represent the north-
ern population of Belgium, and 3) the large sample size
calculated as such to demonstrate differences between
intervention and control group. A potential pitfall of this
study is the long follow-up, i.e. until the end of the sub-
sequent pregnancy, which might result in high drop-out
rates. However, possible drop-outs were considered in
the power calculations for the needed sample size. This
study therefore has the strong potential to show the ef-
fectiveness of the e-health driven coaching program for
women between and during pregnancies to obtain a
healthy lifestyle, to achieve a healthy weight, and to re-
duce pregnancy- and birth related complications.
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